Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial
Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial
复制标题
DOI：
10.1200/jco.2005.04.032
复制
发表时间：
2005-03-20
影响因子：
45.3
通讯作者：
Recht, A
中科院分区：
文献类型：
--
作者：
Bellon, JR;Come, SE;Recht, A
目的早期乳腺癌患者的最佳化疗与放疗（RT）整合仍不确定。我们提出了一个前瞻性随机试验的长期结果，以解决这个问题。患者和方法244例保守性乳腺手术后随机分配接受12周的环磷酰胺，阿霉素，甲氨蝶呤，氟尿嘧啶，泼尼松（CAMFP）RT（CT-第一）或RT（RT-第一）后。存活患者的中位随访时间为135 months.Results CT-first和RT-first组在任何事件、远处转移或死亡的时间上均无显著差异。结论在乳腺癌保守性手术患者中，辅助化疗前给予RT无明显优势。然而，这项研究没有足够的统计学把握度来排除任何一种序列的临床重要生存获益。(c)2005年，美国临床肿瘤学会。
Purpose The optimal integration of chemotherapy with radiation (RT) for patients with early-stage breast cancer remains uncertain. We present the long-term results of a prospective randomized trial to address this question.Patients and Methods Two hundred forty-four patients were randomly assigned after conservative breast surgery to receive 12 weeks of cyclophosphamide, doxorubicin, methotrexate, fluorouracil, and prednisone (CAMFP) before RT (CT-first) or after RT (RT-first). Median follow-up for surviving patients was 135 months.Results There were no significant differences between the CT-first and RT-first arms in time to any event, distant metastasis, or death. Sites of first failure were also not significantly different.Conclusion Among breast cancer patients treated with conservative surgery, there is no advantage to giving RT before adjuvant chemotherapy. However, this study does not have enough statistical power to rule out a clinically important survival benefit for either sequence. (c) 2005 by American Society of Clinical Oncology.